Search research articles
Contact Us
Filters
Showing results (21-30 of 145) with videos related to
Page
of 15
Sort By:
Drugs
|
May 1, 1996
Current knowledge and future prospects for the use of HIV protease inhibitors
G Moyle, B Gazzard
Genitourinary Medicine
|
August 1, 1996
The role of HIV-proteinase inhibitors
B Gazzard, G Moyle
Lancet (London, England)
|
August 5, 1998
1998 revision to the British HIV Association guidelines for antiretroviral treatment of HIV seropositive individuals. BHIVA Guidelines Writing Committee
B Gazzard, G Moyle
Expert Opinion on Investigational Drugs
|
February 1, 1997
To sequence or not to sequence?
B Gazzard, G Moyle
AIDS (London, England)
|
March 1, 1997
The development of resistance of HIV-1 to zalcitabine
C Craig, G Moyle
The AIDS Reader
|
September 1, 2000
Switching from a PI-based to a PI-sparing regimen for management of metabolic or clinical fat redistribution
G Moyle, C Baldwin
HIV Medicine
|
April 28, 2007
Relative antiviral efficacy of ritonavir-boosted darunavir and ritonavir-boosted tipranavir vs. control protease inhibitor in the POWER and RESIST trials
A Hill, G Moyle
Sexually Transmitted Infections
|
August 17, 1999
Commentary: resistance testing--a clinical perspective
B G Gazzard, G Moyle
The American Journal of Medicine
|
March 1, 1995
Foscarnet or ganciclovir for treatment of AIDS and CMV retinitis
G Moyle, B G Gazzard
Nature
|
November 11, 2005
Single origin of a pan-Pacific bird group and upstream colonization of Australasia
Christopher E Filardi, Robert G Moyle
Page
of 15
Search research articles
Search
Showing results (21-30 of 145) with videos related to
Sort By:
Page
of 15
Drugs
|
May 1, 1996
Current knowledge and future prospects for the use of HIV protease inhibitors
G Moyle, B Gazzard
Genitourinary Medicine
|
August 1, 1996
The role of HIV-proteinase inhibitors
B Gazzard, G Moyle
Lancet (London, England)
|
August 5, 1998
1998 revision to the British HIV Association guidelines for antiretroviral treatment of HIV seropositive individuals. BHIVA Guidelines Writing Committee
B Gazzard, G Moyle
Expert Opinion on Investigational Drugs
|
February 1, 1997
To sequence or not to sequence?
B Gazzard, G Moyle
AIDS (London, England)
|
March 1, 1997
The development of resistance of HIV-1 to zalcitabine
C Craig, G Moyle
The AIDS Reader
|
September 1, 2000
Switching from a PI-based to a PI-sparing regimen for management of metabolic or clinical fat redistribution
G Moyle, C Baldwin
HIV Medicine
|
April 28, 2007
Relative antiviral efficacy of ritonavir-boosted darunavir and ritonavir-boosted tipranavir vs. control protease inhibitor in the POWER and RESIST trials
A Hill, G Moyle
Sexually Transmitted Infections
|
August 17, 1999
Commentary: resistance testing--a clinical perspective
B G Gazzard, G Moyle
The American Journal of Medicine
|
March 1, 1995
Foscarnet or ganciclovir for treatment of AIDS and CMV retinitis
G Moyle, B G Gazzard
Nature
|
November 11, 2005
Single origin of a pan-Pacific bird group and upstream colonization of Australasia
Christopher E Filardi, Robert G Moyle
Page
of 15